UnitedHealth or Humana: Which Managed Care Stock Had the Healthiest Returns in April?

The April scoreboard is in for managed care. UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock and Humana (NYSE:HUM) stock both staged impressive rallies, yet UnitedHealth won by just a few basis points (bps).

UNH stock climbed 37% in April, finishing at $370.48 on April 30. HUM stock rose 36%, closing at $236.44. It’s a photo finish, but UnitedHealth wins the month.

The deeper tell is positioning. UnitedHealth stock is now up 11.63% year to date (YTD), while Humana stock is down 9.14% YTD. The recovery is broader and more durable for UNH, and it’s important to consider the reasons for the divergence.

Shared Catalysts Powered the Rebound

Both names entered April deeply oversold after a brutal 2025 of medical loss ratio (MLR) pressure and Medicare Advantage (MA) reimbursement worry. The first jolt came on April 7, when CMS finalized a 2% increase in MA payment rates for 2027, releasing over $13 billion in additional payments into the program.

UNH stock rocketed roughly 11% on the rate news, while HUM popped about 9% to 11%. The decision retained the 2024 risk adjustment model, which lifted a major regulatory overhang for both insurers.

News sentiment confirmed the shift. UNH scored 0.749169 (Bullish) and HUM scored 0.726921 (Bullish) on rate-decision day, the highest readings of the month for either name.

Hospital data added fuel. Softer Q1 2026 hospital volumes at peers like HCA Healthcare (NYSE:HCA) implied lower utilization, which translates to lower medical costs for managed care payers. Capital also rotated into defensive names as artificial intelligence (AI) infrastructure stocks wobbled mid-month.

UnitedHealth Earnings Sealed the Lead

UnitedHealth reported Q1 2026 results on April 21 and delivered a clean beat. Adjusted earnings per share (EPS) came in at $7.23 versus $6.61 expected, with revenue of $111.72 billion.

UnitedHealth’s medical cost ratio improved 90 bps to 84%, and management raised full-year adjusted EPS guidance to greater than $18.25. CEO Stephen Hemsley asserted that UnitedHealth is “continuing to help simplify and modernize health care… bringing greater value, affordability, transparency and connectivity.”

Bank of America followed with an upgrade to Buy and a $435 price target, raised from $405. UnitedHealth’s diversified Optum platform, spanning pharmacy benefit manager (PBM), OptumHealth, and OptumInsight, gives it exposure outside pure insurance that Humana cannot match.

Humana Closes the Gap But Trails

Humana reported Q1 2026 on April 29, posting adjusted EPS of $10.31 versus $10.20 expected on revenue of $39.65 billion, up 23% year over year (YoY).

Humana’s individual MA membership grew about 22% YTD, adding roughly 1,144,000 members. CEO Jim Rechtin called it a “solid start to the year” with operating execution setting up the future. Humana affirmed full-year adjusted EPS guidance of at least $9 and revenue of at least $160 billion.

Wall Street price targets climbed too. Guggenheim raised HUM to $269 from $252, and UBS lifted HUM to $262 from $195. Humana’s heavier MA concentration leaves it more exposed to Star Ratings headwinds and v28 risk model phase-in than UnitedHealth.

Bull and Bear Cases Heading Into May

The bull case for both stocks rests on demographic tailwinds, specialty drug volume growth, and an improving MA rate environment heading into 2027 bidding. For broader context on how investors are reading the sector, see this recent April managed care comparison on UnitedHealth and Humana.

Cash generation underscores the recovery. UnitedHealth produced $8.91 billion in operating cash flow (1.4x net income), while Humana delivered $1.25 billion, up 279% YoY. Both companies are reloading buyback firepower into a still-skeptical tape.

The bear case is real. Regulatory risk persists, MLR pressure could reaccelerate, and valuations have stretched after the rally. UnitedHealth stock is still down 8% over the past year, and Humana stock is down 9.1%, so neither has fully healed.

Watch for whether MLR trend data, MA rate finalization, and the next round of analyst notes confirm the cost-trend thaw. The prudent investors might trim exposure into strength, given how much good news has already priced in. UnitedHealth stock won in April, and May’s price action will decide if the lead holds.